Cancer of the corpus uteri

[1]  A. Lopes,et al.  Laparoscopy versus laparotomy for the management of early stage endometrial cancer. , 2018, The Cochrane database of systematic reviews.

[2]  Cornelis J H van de Velde,et al.  No Increased Risk of Second Cancer After Radiotherapy in Patients Treated for Rectal or Endometrial Cancer in the Randomized TME, PORTEC-1, and PORTEC-2 Trials. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  P. Escobar,et al.  A phase II trial of paclitaxel, carboplatin, and bevacizumab in advanced and recurrent endometrial carcinoma (EMCA). , 2015, Gynecologic oncology.

[4]  T. Baba,et al.  Time Interval Between Endometrial Biopsy and Surgical Staging for Type I Endometrial Cancer: Association Between Tumor Characteristics and Survival Outcome , 2015, Obstetrics and gynecology.

[5]  E. Oliva,et al.  Significance of Lymphovascular Space Invasion in Uterine Serous Carcinoma: What Matters More; Extent or Presence? , 2015, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[6]  C. Houser,et al.  Neoadjuvant radiotherapy with or without chemotherapy followed by extrafascial hysterectomy for locally advanced endometrial cancer clinically extending to the cervix or parametria. , 2014, Gynecologic oncology.

[7]  M. Einstein,et al.  Obesity and Age at Diagnosis of Endometrial Cancer , 2014, Obstetrics and gynecology.

[8]  C. Eng,et al.  Equality in lynch syndrome screening: why should we hold patients with endometrial cancer to a different standard? , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  L. Blomqvist,et al.  Imaging in endometrial cancer. , 2014, Best practice & research. Clinical obstetrics & gynaecology.

[10]  A. Stiggelbout,et al.  Treatment preferences and involvement in treatment decision making of patients with endometrial cancer and clinicians , 2014, British Journal of Cancer.

[11]  F. Bray,et al.  Trends in corpus uteri cancer mortality in member states of the European Union. , 2014, European journal of cancer.

[12]  A. Lopes,et al.  Adjuvant chemotherapy for advanced endometrial cancer. , 2014, The Cochrane database of systematic reviews.

[13]  F. Clavel-Chapelon,et al.  A suggested modification to FIGO stage I endometrial cancer. , 2014, Gynecologic oncology.

[14]  R. Rouzier,et al.  Prognostic factors of oncologic and reproductive outcomes in fertility-sparing management of endometrial atypical hyperplasia and adenocarcinoma: systematic review and meta-analysis. , 2014, Fertility and sterility.

[15]  D. Fishman,et al.  Survival analysis of robotic versus traditional laparoscopic surgical staging for endometrial cancer. , 2014, American journal of obstetrics and gynecology.

[16]  H. Yoshikawa,et al.  Surgery for endometrial cancers with suspected cervical involvement: is radical hysterectomy needed (a GOTIC study)? , 2013, British Journal of Cancer.

[17]  M. Sherman,et al.  Recent changes in endometrial cancer trends among menopausal-age U.S. women. , 2013, Cancer epidemiology.

[18]  K. Bertelsen,et al.  Omitting Adjuvant Radiotherapy in Endometrial Cancer Increases the Rate of Locoregional Recurrences but Has no Effect on Long-Term Survival: The Danish Endometrial Cancer Study , 2013, International Journal of Gynecologic Cancer.

[19]  Meenakshi Singh,et al.  A phase II evaluation of gefitinib in the treatment of persistent or recurrent endometrial cancer: a Gynecologic Oncology Group study. , 2013, Gynecologic oncology.

[20]  J. Ferlay,et al.  Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. , 2013, European journal of cancer.

[21]  R. Rouzier,et al.  Safety of uterine and/or ovarian preservation in young women with grade 1 intramucous endometrial adenocarcinoma: a comparison of survival according to the extent of surgery. , 2012, Fertility and sterility.

[22]  H. Putter,et al.  Five-year quality of life of endometrial cancer patients treated in the randomised Post Operative Radiation Therapy in Endometrial Cancer (PORTEC-2) trial and comparison with norm data. , 2012, European journal of cancer.

[23]  D. Miller,et al.  Late-Breaking Abstract 1: Randomized phase III noninferiority trial of first line chemotherapy for metastatic or recurrent endometrial carcinoma: A Gynecologic Oncology Group study , 2012 .

[24]  V. Gebski,et al.  Improved surgical safety after laparoscopic compared to open surgery for apparent early stage endometrial cancer: results from a randomised controlled trial. , 2012, European journal of cancer.

[25]  M. Ugur,et al.  Intraoperative frozen section is essential for assessment of myometrial invasion but not for histologic grade confirmation in endometrial cancer: a ten-year experience , 2012, Archives of Gynecology and Obstetrics.

[26]  Jason D. Wright,et al.  Comparative effectiveness of robotic versus laparoscopic hysterectomy for endometrial cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  C. Aghajanian,et al.  Phase II trial of combination bevacizumab and temsirolimus in the treatment of recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study. , 2012, Gynecologic oncology.

[28]  R. Barakat,et al.  Recurrence and survival after random assignment to laparoscopy versus laparotomy for comprehensive surgical staging of uterine cancer: Gynecologic Oncology Group LAP2 Study. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  M. Bernardini,et al.  Surgical Outcome of Robotic Surgery in Morbidly Obese Patient With Endometrial Cancer Compared to Laparotomy , 2012, International Journal of Gynecologic Cancer.

[30]  R. Bristow,et al.  Recurrence patterns and surveillance for patients with early stage endometrial cancer. , 2011, Gynecologic oncology.

[31]  H. Mackay,et al.  Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  K. Leslie,et al.  Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  E. Morii,et al.  Intraoperative Frozen Section Assessment of Myometrial Invasion and Histology of Endometrial Cancer Using the Revised FIGO Staging System , 2011, International Journal of Gynecologic Cancer.

[34]  J. Chan,et al.  Influence of gynecologic oncologists on the survival of patients with endometrial cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  R. Broaddus,et al.  A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma , 2010, Cancer.

[36]  A. Mueck,et al.  Hormonal contraception and risk of endometrial cancer: a systematic review. , 2010, Endocrine-related cancer.

[37]  P. Disaia.  Predicting parametrial involvement in endometrial cancer: is this the end for radical hysterectomies in stage II endometrial cancers? , 2010, Obstetrics and gynecology.

[38]  Brigid M Lynch,et al.  State of the epidemiological evidence on physical activity and cancer prevention. , 2010, European journal of cancer.

[39]  P. Zola,et al.  Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer--results from two randomised studies. , 2010, European journal of cancer.

[40]  A. Jemal,et al.  Cancer Statistics, 2010 , 2010, CA: a cancer journal for clinicians.

[41]  A. V. D. Van Der Zee,et al.  Safety of laparoscopy versus laparotomy in early-stage endometrial cancer: a randomised trial. , 2010, The Lancet. Oncology.

[42]  R. Bristow,et al.  Cytoreductive surgery for advanced or recurrent endometrial cancer: a meta-analysis. , 2010, Gynecologic oncology.

[43]  M. Quinn,et al.  Predictive Value of Magnetic Resonance Imaging in Assessing Myometrial Invasion in Endometrial Cancer: Is Radiological Staging Sufficient for Planning Conservative Treatment? , 2010, International Journal of Gynecologic Cancer.

[44]  M. Kaneuchi,et al.  Survival effect of para-aortic lymphadenectomy in endometrial cancer (SEPAL study): a retrospective cohort analysis , 2010, The Lancet.

[45]  H. Putter,et al.  Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial , 2010, The Lancet.

[46]  M. Dimopoulos,et al.  Endometrial Cancer: What Is New in Adjuvant and Molecularly Targeted Therapy? , 2010, Obstetrics and gynecology international.

[47]  R. Barakat,et al.  Laparoscopy compared with laparotomy for comprehensive surgical staging of uterine cancer: Gynecologic Oncology Group Study LAP2. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  L. Ramondetta,et al.  Node-positive adenocarcinoma of the endometrium: outcome and patterns of recurrence with and without external beam irradiation. , 2009, Gynecologic oncology.

[49]  Hein Putter,et al.  Quality of life after pelvic radiotherapy or vaginal brachytherapy for endometrial cancer: first results of the randomized PORTEC-2 trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  B. van Calster,et al.  Neoadjuvant chemotherapy followed by interval debulking surgery in patients with serous endometrial cancer with transperitoneal spread (stage IV): a new preferred treatment? , 2009, British Journal of Cancer.

[51]  V. Torri,et al.  Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial. , 2009, Journal of the National Cancer Institute.

[52]  P. Schiff,et al.  Optimizing the management of stage II endometrial cancer: the role of radical hysterectomy and radiation. , 2009, American journal of obstetrics and gynecology.

[53]  T. Whelan,et al.  Adjuvant external beam radiotherapy in the treatment of endometrial cancer (MRC ASTEC and NCIC CTG EN.5 randomised trials): pooled trial results, systematic review, and meta-analysis , 2009, The Lancet.

[54]  M. Parmar,et al.  Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study , 2009, The Lancet.

[55]  H. Andersson,et al.  Treatment of primary advanced and recurrent endometrial carcinoma with a combination of carboplatin and paclitaxel— long‐ term follow‐ up , 2008, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.

[56]  H. Kuwano,et al.  Expression of an activated mammalian target of rapamycin in adenocarcinoma of the cervix: A potential biomarker and molecular target therapy , 2008, Molecular carcinogenesis.

[57]  E. Sartori,et al.  Pattern of failure and value of follow-up procedures in endometrial and cervical cancer patients. , 2007, Gynecologic oncology.

[58]  G. Phillips,et al.  Clinical and Pathologic Correlates in Surgical Stage II Endometrial Carcinoma , 2007, Obstetrics and gynecology.

[59]  W. Frankel,et al.  Screening for Lynch syndrome (hereditary nonpolyposis colorectal cancer) among endometrial cancer patients. , 2006, Cancer research.

[60]  P. Zola,et al.  Adjuvant chemotherapy vs radiotherapy in high-risk endometrial carcinoma: results of a randomised trial , 2006, British Journal of Cancer.

[61]  T. Oliver,et al.  Follow-up after primary therapy for endometrial cancer: a systematic review. , 2006, Gynecologic oncology.

[62]  C. Morrison,et al.  HER-2 is an independent prognostic factor in endometrial cancer: association with outcome in a large cohort of surgically staged patients. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[63]  A. Berchuck,et al.  Retrospective analysis of selective lymphadenectomy in apparent early-stage endometrial cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[64]  J. Fanning,et al.  Carboplatin and paclitaxel for the treatment of advanced or recurrent endometrial cancer. , 2005, American journal of obstetrics and gynecology.

[65]  D. Cruickshank,et al.  The role of routine follow‐up after gynecological malignancy , 2005, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.

[66]  R. Burger,et al.  Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a gynecologic oncology group study. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[67]  M. Maiman,et al.  A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. , 2004, Gynecologic oncology.

[68]  R. Burger,et al.  Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[69]  P. Roland,et al.  The benefits of a gynecologic oncologist: a pattern of care study for endometrial cancer treatment. , 2004, Gynecologic oncology.

[70]  Robert Almassy,et al.  Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361. , 2004, Journal of the National Cancer Institute.

[71]  N. Ferrara,et al.  The biology of VEGF and its receptors , 2003, Nature Medicine.

[72]  A. Dove.  Tumor cells , 2003, The Journal of Cell Biology.

[73]  P. Koper,et al.  Survival after relapse in patients with endometrial cancer: results from a randomized trial. , 2003, Gynecologic oncology.

[74]  M. Piccart,et al.  Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: definitive results of a randomised study (55872) by the EORTC Gynaecological Cancer Group. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[75]  A. Harris,et al.  The angiogenic “vascular endothelial growth factor/flk‐1(KDR) receptor” pathway in patients with endometrial carcinoma , 2001, Cancer.

[76]  E. Sartori,et al.  Clinical behavior of 203 stage II endometrial cancer cases: The impact of primary surgical approach and of adjuvant radiation therapy , 2001, International Journal of Gynecologic Cancer.

[77]  K. Swenerton,et al.  Paclitaxel and carboplatin, alone or with irradiation, in advanced or recurrent endometrial cancer: a phase II study. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[78]  M. J. Webb,et al.  Role of wide/radical hysterectomy and pelvic lymph node dissection in endometrial cancer with cervical involvement. , 2001, Gynecologic oncology.

[79]  A. Mundt,et al.  Significant pelvic recurrence in high-risk pathologic stage I--IV endometrial carcinoma patients after adjuvant chemotherapy alone: implications for adjuvant radiation therapy. , 2001, International journal of radiation oncology, biology, physics.

[80]  D. Mukhopadhyay,et al.  Vascular Permeability Factor (VPF)/Vascular Endothelial Growth Factor (VEGF) Receptor-1 Down-modulates VPF/VEGF Receptor-2-mediated Endothelial Cell Proliferation, but Not Migration, through Phosphatidylinositol 3-Kinase-dependent Pathways* , 2001, The Journal of Biological Chemistry.

[81]  C. Haie-meder,et al.  Value and cost evaluation of routine follow-up for patients with clinical stage I/II endometrial cancer. , 2001, European journal of cancer.

[82]  P. Koper,et al.  Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma. , 2000 .

[83]  E. Trimble,et al.  SEER data, corpus uteri cancer: treatment trends versus survival for FIGO stage II, 1988-1994. , 1999, Gynecologic oncology.

[84]  G. Neufeld,et al.  Vascular endothelial growth factor (VEGF) and its receptors , 1999, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[85]  S. Broste,et al.  Surgery Without Radiotherapy for Primary Treatment of Endometrial Cancer , 1998, Obstetrics and gynecology.

[86]  L. Akslen,et al.  Recurrence of endometrial carcinoma and the value of routine follow up , 1997, British journal of obstetrics and gynaecology.

[87]  D. Coyle,et al.  Costs and benefits of routine follow-up after curative treatment for endometrial cancer. , 1997, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[88]  N. Kinukawa,et al.  Angiogenesis in endometrial carcinoma , 1997, Cancer.

[89]  I. Duncan,et al.  Is there any value in the long term follow up of women treated for endometrial cancer? , 1996, British journal of obstetrics and gynaecology.

[90]  R. Lilford,et al.  Adjuvant progestagen therapy for the treatment of endometrial cancer: review and meta-analyses of published randomised controlled trials. , 1996, European journal of obstetrics, gynecology, and reproductive biology.

[91]  L. Valentin,et al.  TRANSVAGINAL ULTRASONOGRAPHY OF THE ENDOMETRIUM IN WOMEN WITH POSTMENOPAUSAL BLEEDING: A NORDIC MULTICENTER STUDY , 1996 .

[92]  A. Berchuck,et al.  Postsurgical surveillance of patients with FIGO stage I/II endometrial adenocarcinoma. , 1995, Gynecologic oncology.

[93]  Y. Song,et al.  Detection of Deep Myometrial Invasion in Endometrial Carcinoma: Comparison of Trans vaginal Ultrasound, CT, and MRI , 1995, Journal of computer assisted tomography.

[94]  L. Valentin,et al.  Transvaginal ultrasonography of the endometrium in women with postmenopausal bleeding--a Nordic multicenter study. , 1995, American journal of obstetrics and gynecology.

[95]  G. Stuart,et al.  An evaluation of routine follow-up of patients treated for endometrial carcinoma. , 1994, Gynecologic oncology.

[96]  P. Klemi,et al.  Staging of Uterine Endometrial Carcinoma with Ultra‐Low Field (0.02 T) MRI: A Comparative Study with CT , 1993, Journal of computer assisted tomography.

[97]  C. Belloni,et al.  Estimating the depth of myometrial involvement by endometrial carcinoma: efficacy of transvaginal sonography vs MR imaging. , 1993, AJR. American journal of roentgenology.

[98]  J. Folkman.  What is the evidence that tumors are angiogenesis dependent? , 1990, Journal of the National Cancer Institute.

[99]  D. Goeddel,et al.  Vascular endothelial growth factor is a secreted angiogenic mitogen. , 1989, Science.

[100]  C. Partain,et al.  Preoperative assessment of myometrial invasion of endometrial adenocarcinoma by sonography (US) and magnetic resonance imaging (MRI) , 1989, Gynecologic oncology.

[101]  H. Dvorak,et al.  Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. , 1983, Science.

[102]  V. Abeler,et al.  Postoperative External Irradiation and Prognostic Parameters in Stage I Endometrial Carcinoma: CLINICAL AND HISTOPATHOLOGIC STUDY OF 540 PATIENTS , 1980, Obstetrics and gynecology.

[103]  G. Pond,et al.  Impact of wait times on survival for women with uterine cancer. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[104]  P. Escobar,et al.  Primary radiation therapy for medically inoperable patients with clinical stage I and II endometrial carcinoma. , 2012, Gynecologic oncology.

[105]  A. Cust.  Physical activity and gynecologic cancer prevention. , 2011, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[106]  Matthew Burnell,et al.  Sensitivity of transvaginal ultrasound screening for endometrial cancer in postmenopausal women: a case-control study within the UKCTOCS cohort. , 2011, The Lancet. Oncology.

[107]  D. Timmerman,et al.  Should we screen for endometrial cancer? , 2011, The Lancet. Oncology.

[108]  M. Munsell,et al.  A phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[109]  J. Berek,et al.  Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study. , 2010, Gynecologic oncology.

[110]  J. Dungan.  Laparoscopy Compared With Laparotomy for Comprehensive Surgical Staging of Uterine Cancer: Gynecologic Oncology Group Study LAP2 , 2010 .

[111]  R. Wenham,et al.  The molecular biology of endometrial cancers and the implications for pathogenesis, classification, and targeted therapies. , 2009, Cancer control : journal of the Moffitt Cancer Center.

[112]  O. Brawley,et al.  Cancer screening in the United States, 2009: A review of current American Cancer Society guidelines and issues in cancer screening , 2009, CA: a cancer journal for clinicians.

[113]  Nobuyuki Susumu,et al.  Randomized phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate- and high-risk endometrial cancer: a Japanese Gynecologic Oncology Group study. , 2008, Gynecologic oncology.

[114]  G. Thomas,et al.  Endometrial cancer--revisiting the importance of pelvic and para aortic lymph nodes. , 2007, Gynecologic oncology.

[115]  Patrick Neven,et al.  Endometrial cancer. , 2005, Lancet.

[116]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.

[117]  R. Pearcey,et al.  Endometrial carcinoma--relative effectiveness of adjuvant irradiation vs therapy reserved for relapse. , 1997, Gynecologic oncology.

[118]  I. Strøyer,et al.  Adjuvant radiation therapy is not necessary in the management of endometrial carcinoma stage I, low‐risk cases , 1996 .

[119]  E. Partridge,et al.  Adenocarcinoma of the endometrium: survival comparisons of patients with and without pelvic node sampling. , 1995, Gynecologic oncology.

[120]  M. Randall,et al.  Whole abdominal radiotherapy versus combination chemotherapy with doxorubicin and cisplatin in advanced endometrial carcinoma (phase III): Gynecologic Oncology Group Study No. 122. , 1995, Journal of the National Cancer Institute. Monographs.

[121]  Y. Yamashita,et al.  Assessment of myometrial invasion by endometrial carcinoma: transvaginal sonography vs contrast-enhanced MR imaging. , 1993, AJR. American journal of roentgenology.

[122]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[123]  R. Kurman,et al.  The behavior of endometrial hyperplasia. A long-term study of “untreated” hyperplasia in 170 patients , 1986 .